



Gynecologic Oncology

University Health Network /
Sinai Health Systems

Annual Research Report July 2024 - June 2025



UNIVERSITY OF
TORONTO

MOUNT SINAI HOSPITAL
Joseph and Wolf Lebovic Health Complex



Table of Contents

Goals and Vision Statement	3
Surgeon-Investigators	4
Research Team	7
Highlights	8
Funding Awards	9
Active Studies and Recruitment	11
Presentations	17
Publications	23



Vision and Goals:



To expand and promote **clinical, translational and educational research** by integration in the clinical care setting.



To become Canada's **leader** in Gynecologic Oncology, **improving outcomes** for all women with gynecologic cancer through excellence in patient care, research and education.

Our integrated approach includes:



Active Screening

Pre-screening gynecologic oncology clinics to identify patients eligible for our studies.



Biobanking

Collecting and banking blood samples from ovarian cancer patients and coordinating tissue collection for research.



Collaboration

Building relationships across disciplines for novel and innovative translational research.



Meet the Surgeon-Investigators



Dr. Marcus Bernardini

Dr. Bernardini is the Division Head of Gynecologic Oncology at the University Health Network. His research interests include: understanding the role of precursor lesions in high grade serous ovarian cancer, as well as cytoreductive surgery for later stage disease. He co-leads the ovarian cytoreductive program as well as CANSTIC, a Pan-Canadian study looking at treatment and outcomes of ovarian pre-cursor lesions. He is also lead investigator of the Early Stage Cohort of CANSTAMP.



Dr. Sarah Ferguson

Dr. Ferguson is Professor and Vice Chair of Research in the Department of Obstetrics and Gynecology at the University of Toronto. As well she is Head of Research and Sinai Health System/University Health Network/Women's College Hospital. Her research interests include surgical clinical trials, patient-reported outcomes, survivorship and sexual health in gynecologic cancer. She also leads an extensive research program in endometrial cancer, with a focus on outcomes by molecular subtype, sentinel lymph node procedures, fertility preservation and hereditary cancer syndromes such as Lynch Syndrome. She has published pivotal surgical clinical trials including, Assessment of Sentinel Lymph Node Biopsy vs Lymphadenectomy for Intermediate- and High-Grade Endometrial Cancer Staging published in JAMA Surgery and Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy in Journal of Clinical Oncology. She is currently the principal investigator for the B-FIERCE trial and co-principal investigator for an upcoming clinical trial, WE-FIERCE.



Dr. Stephane Laframboise

Dr. Laframboise is the Director of the Gynecology Oncology Fellowship Program at Princess Margaret. Her research interests are in vulvar cancer, with particular interest in psychosexual health, treatment outcomes and recurrence patterns. She will be launching STRIVE, a prospective multicenter study to evaluate margin assessment and role of repeat excision versus surveillance in HPV-independent and HPV-associated squamous cell carcinoma. Findings from this study may provide evidence for more tailored treatment approaches and improved outcomes for patients with vulvar cancer.



Meet the Surgeon-Investigators



Dr. Cristina Mitric

Dr. Mitric joined the division in 2024. Her clinical and academic interests focus on the integration of immunotherapy and the development of novel therapeutic and diagnostic strategies in gynecologic oncology, with the overarching goal of improving outcomes for patients with gynecologic malignancies. She also has a strong research interest in health economics, particularly in evaluating cost-effectiveness as it relates to surgical management optimization and genetic testing. Dr. Mitric is currently pursuing a Master's degree in Health Services Research at the Institute of Health Policy, Management, and Evaluation at the University of Toronto, where her work examines the clinical and economic implications of genetic testing in rare ovarian cancers.



Dr. Liat Hogen

Dr. Hogen joined the division in 2017. Her research interests include predictive models to guide cytoreductive surgery in advanced ovarian cancer, and management of rare endometriosis-associated subtypes of ovarian cancer. She is leading study on development of an integrated model that leverages genomics and AI to improve surgical outcomes in ovarian cancer. She is also site principal investigator for multiple multicentre international trials in the surgical management of advanced ovarian cancer and is actively advancing adoption of HIPEC for appropriate patients.



Dr. Genevieve Bouchard-Fortier

Dr. Bouchard-Fortier joined the division in 2016. Her research is focused on gestational trophoblastic disease and improving the quality of care of gynecologic oncology patients by developing and measuring quality metrics. Dr. Bouchard-Fortier has a number of projects using provincial database at IC/ES. In addition, she is leading a comprehensive quality improvement project to reduce perioperative blood transfusions in surgical gynecologic oncology patients.



Meet the Surgeon-Investigators



Dr. Rachel Soyoun Kim

Dr. Kim joined the division in 2022. Her research aims to personalize the diagnostic and treatment paradigm for patients with gynecological malignancies. In particular, she is interested in improving outcomes for young patients with endometrial cancer, and exploring the role of circulating tumour DNA for endometrial cancer surveillance. She is currently the lead investigator for a study to address fertility distress in young patients with endometrial cancer and will co-lead an upcoming clinical trial WE-FiERCE.




Dr. Lauren Philp

Dr Lauren Philp is an assistant professor in the division of Gynecologic Oncology. She completed her residency training in OBGYN at the University of Toronto during which time she completed a MSc. through the clinician investigator program. She then undertook a clinical and research fellowship in Gynecologic Oncology at the Massachusetts General Hospital / Harvard Medical School in Boston, MA. She joined the faculty at the University of Toronto in 2022. Her research interests are centered on advanced ovarian cancer and translational science, specifically looking at the use of novel methods for intra-operative imaging and surgical guidance. Her research enables more accurate detection and personalized effective treatment. She is also actively involved in quality improvement and use of patient reported outcomes to inform and enhance care.



Meet the Research Team



Vanessa Ballin

Vanessa joined the Division of Gynecologic Oncology at Princess Margaret Cancer Centre in September of 2022. In her role as Clinical Research Manager she supports clinician-investigators in the planning, development, and initiation of new and innovative research projects, and provides oversight for all operational aspects of existing studies.



Ferdous Parveen

Ferdous joined the Comprehensive Ovarian Tumours Program in November 2022. She is responsible for coordinating all ovarian cancer-related surgical and quality of life studies, including the LANCE, OCHP, FAST HOC, FARGO, Bio Diva, and Nutrition in Ovarian Cancer studies.



Tara Zad

Tara joined the Division of Gynecologic Oncology at Princess Margaret Cancer Centre in October 2023. She is involved in screening, enrolling, and coordinating participants for the B-FiERCE, ROCC, WE-FiERCEQ, EN10, and EN11 clinical trials. In addition to coordination, she is responsible for REB documentation and data management for various prospective and retrospective studies.



Joey Wong

Joey joined the Division of Gynecologic Oncology at Princess Margaret Cancer Centre as a volunteer in January 2025 and later as a Clinical Research Study Assistant in June 2025. She is involved in screening, enrolling, and coordinating participants for B-FiERCE. She is also screening participants for RESILIENCE. In addition to coordination, she is responsible for building and managing endometrial cancer registry.



Grant Funding

\$3,453,135 awarded



Patient Participation

17 actively recruiting studies




Publications

43 Total
12 First/Last Author
31 Co-Author



Funding Awards



Bouchard-Fortier G. 2024 Fellberg Family Award, Department of Obstetrics and Gynaecology, Mount Sinai Hospital. **20,000 CAD** (2024 July-2026 June). Patterns of care of gestational trophoblastic neoplasia in Ontario: a population-based study. (Collaborator(s): Gien L, Swift B)

Bouchard-Fortier G, Ferguson SE. Department of Obstetrics and Gynaecology, Mount Sinai Hospital. **10,000 CAD** (2024-Sept-2026 June). Rising Trends in Cervical cancer: Patterns, Causes and Implications. (Collaborator(s): Gien L, Kupets R, Cusimano M)

Bouchard-Fortier G, Lim J. 2025 Joan Murphy Award. Department of Obstetrics and Gynecology, Mount Sinai Hospital. **10,000 CAD** (2025-April -2027 April). Impact of marginalization on survival and healthcare utilization in epithelial ovarian cancer: an Ontario population-based study. (Collaborators: **Philp L**, Gien L, Grewat K)

Kim SR. Joan Murphy Divisional Award in Gynecologic Oncology. Department of Obstetrics and Gynecology. **10,000 CAD** (2024 Jul-2026 Jul). Acceptance of weight loss medications in women with atypical hyperplasia or carcinoma of the endometrium as part of fertility preservation treatment: A qualitative study. (Collaborators: **Ferguson SE**, Dzyubak O, Simpson A, Gesink D)



Bosma, R (NPA), Clarke, H. Health Canada Substance Use and Addictions Program. **1,200,000 CAD** (2025-Feb). SafeOp Project: Prevention of chronic pain and opioid harms through the formalization and knowledge mobilization of best practices in perioperative pain management. (Collaborators: Ward S, Di Renna T, Bonin R, Furlan A, Pearsall E, Lomanowska A, Veiga L, Soucy B, Hudspith M, Birnie K, McCann KJ, Broderick C, LeBlanc C, Kulkarni G, **Bouchard-Fortier G**, Roche-Nagle G, Lee J, Ross K, Levinson W, Buckley N, Busse J, Hyland S)

Rajesh Bhayana. Cancer Digital Intelligence (CDI) Grand Challenge, University Health Network. **250,000 CAD**. (2024- Nov). Artificial Intelligence for Risk Stratification of Liver and Ovarian Lesions (LI-RADS and ORADS MRI) from Reports. (Collaborators: Ganor-Shwaartz C, Krishna S, Haider M, Deng Y, **Bouchard-Fortier G**)

Wilson B. Cancer Research Society Operating Grant. **135,000 CAD**. (2025 Jan – 2027 Aug) Light-Emitting Nanoparticles for Photoimmune Therapy of Ovarian Carcinomatosis. (Collaborators: **Philp L**, Pires L)

Lheureux S. Rodin G. Ovarian Cancer Canada Pragmatic Clinical Trials Competition Grant. **400,000 CAD** (2025 May -2029 May). Prevalence and Experience of Traumatic Stress in Patients with Newly Diagnosed and Recurrent Advanced Ovarian Cancer. (Collaborator: **Philp L**, Hales S, Shapiro G)


MOHCCN Patient Voices in Research Initiative Award. The Terry Fox Institution. **183,500 CAD** (2024 Nov – 2025 Dec). Exploring the perspectives of stakeholders for homologous recombination deficient (HRD) biomarker testing to guide precision medicine for advanced ovarian cancer treatment. (Co-Investigator: **Ferguson SE**)

Cusimano M. Wise Research and Education Institute Research Grant, Lahey Hospital & Medical Center, Burlington, MA, USA. 30,403 USD (**42,630 CAD**) (2025 Jan – 2027 Dec). Association of Bilateral Salpingo-Oophorectomy at Non-Malignant Hysterectomy with Long-Term Morbidity. (Co-Investigators: **Ferguson SE**, Moineedin R, Baxter NN, Gagliardi E, Johnson C, Griffith K)

Terry Fox Research Institute New Frontiers Project Program Grant. **1,192,005 CAD** (2024 July – 2029 June). The Terry Fox New Frontiers Program Project Grant in Porphysome Nanoparticle-Enabled Image-Guided Cancer Interventions. Collaborators: Zheng G, Irish J, Yasufuku K, Weersink R, Lheureux S, Oza A, Ghai S, Kirsch D, McGaha T. (Co-Investigator: **Philp L**, Wilson B)



Active Studies and Recruitment



Bariatric Surgery for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium (B-FiERCE)

PI: Dr. Sarah Ferguson

- Recruitment began in April 2021

B-FiERCE is a feasibility randomized controlled trial to assess the feasibility of addition of bariatric surgery to progestin therapy in women with obesity who have endometrial cancer (Grade 1) or atypical hyperplasia who desire fertility preservation. Recruitment in the academic year 2024-2025 added 7 patients to the trial. We hope to achieve full recruitment by end of 2025.

LANDscape MApping of Epitopes and T cell Receptors for Selected Cancers (LANDMARC)

PI: Dr. Sarah Ferguson

- Recruitment began in December 2020

LANDMARC is a correlative research study aimed at characterizing the T cell mediated immune responses to HPV-related and EBV-related cancers, and hepatocellular carcinoma (HCC). No patients were recruited in 2024-2025.



A Randomized Controlled Trial of Robotic versus Open Surgery for Early Stage Cervical Cancer (ROCC)

PI: Dr. Kristin Bixel

Co-I: Dr. Sarah Ferguson

- Recruitment began in October 2024

ROCC is a randomized controlled trial comparing the 3-year disease-free survival (DFS) for patients who undergo robotic assisted laparoscopy versus open hysterectomy and lymph node assessment for the treatment of early stage uterine cervical cancer. Recruitment from our site in the academic year 2024-2025 added 6 patients to this multi-centered study.

A phase II study of tailored adjuvant therapy in POLE-mutated and p53-wildtype/NSMP early stage endometrial cancer - RAINBO BLUE & TAPER (EN.10)

PI: Dr. Kathy Han

Co-I: Dr. Sarah Ferguson

- Recruitment began in 2023

EN.10 is a phase II trial to investigate the efficacy of a de-escalated adjuvant treatment approach based on tumour molecular status (molecular classification-tailored adjuvant therapy) in patients with endometrial cancer. Recruitment from our site in the academic year 2024-2025 added 5 patients to this multi-centered study.

RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials - MMRD-GREEN trial (EN.11)

PI: Dr. Kathy Han

Co-I: Dr. Ferguson, Dr. Bernardini, Dr. Bouchard-Fortier, Dr. Hogen, Dr. Kim and Dr. Laframboise

- Recruitment began in May 2024

EN.11 is a phase III RCT with the goal of improving recurrence-free survival in patients with high-risk MMRd EC by using adjuvant durvalumab in combination with and following radiotherapy. Recruitment from our site in the academic year 2024-2025 added 4 patients to this multi-centered study.

Using a multimodal and digital intervention to optimize waist circumference, body composition, and cardiometabolic health in endometrial cancer survivors (RESILIENCE)

PI: Dr. Amy A. Kirkham

Co-I: Dr. Sarah Ferguson

- Recruitment began in June 2025

RESILIENCE is a 24-week RCT to evaluate the efficacy of a web-based health platform and line professional support intervention on improving waist circumference and other health outcomes



in endometrial cancer survivors. Recruitment at our site started in Jun 2025. No patients were enrolled in Jun 2025.

Exploring the perspectives of stakeholders for homologous recombination deficient (HRD) biomarker testing to guide precision medicine for advanced ovarian cancer treatment (HRD Testing Study)

PI: Dr. Helen McTaggard-Cowan

Co-I: **Dr. Sarah Ferguson**

- Recruitment began in May 2025

HRD Testing Study is a qualitative study to investigate the knowledge, attitudes and experiences of advanced ovarian cancer patients regarding HRD testing. One-to-one semi-structured interviews via telephone or video will be conducted for all participants to explore patients' belief about HRD testing, perceived benefits and barriers, perceived adherence to treatment and overall understanding and acceptability of HRD testing. No patients were enrolled in the study in May and June 2025.

Acceptance of Weight Loss Medication in Women with Atypical Hyperplasia or Carcinoma of the Endometrium as Part of the Fertility Preservation Treatment: A Qualitative Study (WE-FiERCEQ)

PI: **Dr. Sarah Ferguson, Dr. Rachel Soyoun Kim**

- Recruitment began in May 2025

WE-FiERCEQ is a qualitative study exploring patient perception and attitude towards weight loss medication as an adjunct to fertility-sparing treatment for atypical hyperplasia/ endometrial cancer. Semi-structured interviews will be conducted to understand the motivations behind patients' decision and help incorporate their perspectives into future WE-FiERCE clinical trial design. 5 patients were enrolled in the study in May and June 2025.

Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy (LANCE)

PI: **Dr. Liat Hogen**

- Recruitment began in December 2021

LANCE is a randomized, non-inferior phase III trial examines whether minimally invasive surgery is non-inferior to laparotomy in terms of disease-free survival (DFS) in women with advanced-stage epithelial ovarian cancer who received 3 to 4 cycles of neoadjuvant chemotherapy. Recruitment from our site in the academic year 2024-2025 added 8 patients to this multi-centered study.



The impact of malnutrition on chemotherapy-induced Toxicity in Patients with Ovarian Cancer (Nutrition in OC)

PI: Dr. Marcus Bernardini

- Recruitment began in March 2023

Nutrition in OC is a prospective cohort study to determine whether malnutrition at presentation (defined as PG-SFA SF ≥ 5) is an independent risk factor for grade 3-4 hematologic toxicity as defined by the CTCAE v.5 in patients with ovarian cancer. We successfully enrolled 43 patients for this study in academic year 2024-2025. The study is closed for enrollment on Jan 2025.

Molecular Profiling of Tumour Heterogeneity in High-Grade Serous Ovarian Cancer (OCHP)

PI: Dr. Laurie Ailles

Co-I: Dr. Liat Hogen

- Recruitment began in September 2020

OCHP is a prospective research study which obtains fresh serous ovarian cancer tissue and selected clinical data to explore the differences in cellular subpopulations of serous ovarian cancer by DNA/RNA sequencing, flow cytometry and cell culture assays. 17 patients were enrolled between Jul 2024 and Jun 2025. Study is closed for enrollment in November 2024.

Biomarker Discovery Project in High-Grade Serous Ovarian Cancer (Bio DIVA)

PI: Dr. Amit Oza

Co-I: Dr. Marcus Bernardini

- Recruitment began in January 2023

Bio DIVA is prospective multi-centre non-randomized study with the aim of defining differences in the genomic and immune signature of patients with HGSOC at different time points, and analyze its correlation with outcome in terms of progression free survival and overall survival, particularly comparing patient with short term (1-2 years) versus long term (5-10 years) survival, and correlation to response or resistance to a specific treatment. We successfully enrolled 44 patients in 2024-2025.

68Ga-FAPI PET/CT in the Staging of High-Grade Epithelial Ovarian Cancers: A Pilot Study (FAST HOC)

PI: Dr. Ur Metser

Co-I: Dr. Liat Hogen

- Recruitment began in July 2023

FAST HOC is a prospective study that aims to use a technology called PET-CT that combines a Positron Emission Tomography (PET) scan with a computed tomography (CT) scan. This combined imaging test, where PET and CT data are gathered at one time, will be performed on an integrated



PET-CT scanner located at Princess Margaret Cancer Centre. The purpose of this study is to determine if the use of 68Ga-PNT6555 (FAPI) PET-CT will improve the assessment of disease extent as compared to routine CT scans. Recruitment in 2024-2025 added 18 patients to this study.

Frailty Assessment for Risk Prediction in Gynecologic Oncology patients undergoing surgery and Chemotherapy (FARGO)

PI: Dr. Liat Hogen

- Recruitment began in December 2023

FARGO is a prospective, multi-centre study that aims to investigate whether assessing frailty before treatment can predict post-surgery health complications in patients. With gynecologic cancers (cancers of the uterus, cervix and ovaries) patients experiencing more medical issues as they age, the risks associated with surgical or chemotherapeutic treatments increase. This study will determine if this new approach is more effective than current risk assessment methods by assessing its ability to accurately predict changes in health after surgery. 41 patients were enrolled in the study between July 2024 and June 2025.

Alleviating Traumatic Stress Symptoms in Advanced Ovarian Cancer: A Feasibility Study of a Trauma-Focused Psychotherapeutic Intervention (CALM)

PI: Dr. Gary Rodin

Co-I: Dr. Lauren Philp

- Recruitment began in June 2024

This study is a single-arm phase II trial evaluating CALM-TF, a psychotherapeutic intervention addressing symptom management, changes in self and relationships with others, meaning-making, and future fears, for patients with advanced ovarian cancer. The design is expected to enroll 60 patients (30 newly diagnosed, 30 with recurrence) with assessments at baseline, 3 and 6 months, plus qualitative interviews. The goal is to assess feasibility and acceptability of CALM for this population, exploring its impact early in the illness trajectory. 46 patients were enrolled between July 2024 and June 2025.

Canadian multi-arm multi-stage randomized controlled trial assessing front line and maintenance treatment in serous or p53 mutant endometrial cancer (CANSTAMP)

PI: Dr. Amit Oza

Co-I: Dr. Marcus Bernardini

- Recruitment began in 2023

This is a phase II RCT to compare the disease-free survival (DFS) of patients with early stage EC randomized to pelvic external beam radiotherapy (EBRT) versus vaginal brachytherapy after completing adjuvant platinum-based chemotherapy. Also, this study aims to compare the



progression free survival (PFS) of advanced stage patients randomized to standard of care surveillance versus therapy maintenance. 6 patients were enrolled between Jul 2024 and Jun 2025.

Predicting outcome of cytoreuction in advanced ovarian cancer, using a machine learning algorithm and patterns of disease distribution at laparoscopy (PREDAtoOR)

PI: Dr. Liat Hogen

- Recruitment began in July 2024

PREDAtoOR aims to collect laparoscopic surgery images and employ the latest technology in artificial intelligence and machine learning to develop highly accurate prediction models using these laparoscopy video images. These models will be a valuable tool in determining the success rate of tumor removal during initial surgery and identifying the need for pre-surgery chemotherapy. 49 patients were enrolled in the study between July 2024 and June 2025.



PRESENTATIONS

International

International Gynecologic Cancer Society 2024 Annual Global Meeting. October 16-18, 2024

Oral Plenary Presentations

Cusimano M, Poxon A, Lilian Gien L, Rinku Sutradhar R, Lena Nguyen L, Emily Van De Laar E, Ning Liu N, Ballin V, Watts M, Plante M, **Ferguson SE**. Association of surgical approach with oncologic outcomes in low-risk cervical cancer: population-based cohort study. International Gynecologic Cancer Society 2024 Annual Global Meeting. Dublin, Ireland.

Posters

Braik D, Kasherman L, Gonzalez-Ochoa E, Shukla A, Odujoko O, Lajkosz K, Wang C, Liang T, Grant R, Dhani N, Croke J, **Philp L**, Oza A, Lheureux S. Impact of cultural and linguistic backgrounds on patient care and experience of women with gynecologic malignancies (iCALD-2). The International Gynecologic Cancer Society (IGCS) Annual Global Meeting.

Dzybak O, **Kim SR**, Glass K, Watts M, Tarafdar O, Simpson A, Maganti M, Deljoomanesh S, **Laframboise S, Ferguson SE**. Oncological outcomes in patients undergoing fertility-sparing treatment of atypical hyperplasia and grade 1 cancer of the endometrium using progestin therapy: results of a novel, specialized oncofertility program. International Gynecologic Cancer Society 2024 Annual Global Meeting. Dublin.

Mitric C, Salman L, Swift B, Kupets R, Covens A, Gien L T, Vicus D. Post-operative complications in elderly patients undergoing minimally invasive, same day discharge surgery for gynecologic malignancies. International Gynecologic Cancer Society, Dublin, Ireland.

Mitric C, Salman L, Swift B, Kupets R, Covens A, Gien L T, Vicus D. The impact of operative time in minimally invasive surgery for endometrial cancer. International Gynecologic Cancer Society, Dublin, Ireland.

World Congress on Gestational Trophoblastic Diseases. October 22-25, 2024

Oral Plenary Presentations

Mitric C, Yang K, Bhat G, Lheureux S, **Laframboise S**, Li X, **Bouchard-Fortier G**. Gestational Trophoblastic Neoplasia: Does Centralization of Care Impact Clinical Management? World Congress on Gestational Trophoblastic Diseases, Lyon, France.

Mitric C, Sayyid R, Fleshner N, Look Hong N, **Bouchard-Fortier G**. Hysterectomy versus Chemotherapy for Low-Risk Non-Metastatic Gestational Trophoblastic Neoplasia (GTN): A Cost-Effectiveness Analysis. World Congress on Gestational Trophoblastic Diseases, Lyon, France.



SGO Annual Meeting on Women's Cancer. March 14-17, 2025

Oral Plenary Presentations

L Philp. Ensuring relevance and equity in Patient Reported Outcomes (PROs) in endometrial cancer: The PROMOTE study. The Society of Gynecologic Oncology Annual General Meeting.

Posters

Ahmed A, Saini G, Fazelzad R, Han K, Pugh T, Wong D, Hodgson A, **Ferguson SE, Kim SR.** Prognostic value of circulating tumor DNA in endometrial cancer: a systematic review and meta-analysis. 2025 Society of Gynecology Oncology Annual Meeting on Women's Cancer, Seattle, USA.

Dzyubak O, Moshkovich M, Watts M, Tarafdar O, Lim J, Maganti M, Han K, Hodgson A, **Ferguson SE, Kim SR.** Should lymph node staging be tailored according to molecular profile in endometrial cancer? 2025 Society of Gynecology Oncology Annual Meeting on Women's Cancer, Seattle, USA.

Dzyubak O, Tram T, McCluskey S, **Kim SR, Laframboise S, Philp L, Hogen L, Bernardini M, Ferguson SE, Bouchard-Fortier G.** Tranexamic Acid Use in Advanced Ovarian Cancer Patients Undergoing Cytoreductive Surgery: Quality Improvement Study. SGO, Seattle, WA, USA.

Invited Speaker Presentations

XXII World Congress on Gestational Trophoblastic Diseases. October 22-25, 2024

Bouchard-Fortier G. Predictors of treatment response in gestational trophoblastic disease. XXII World Congress. Lyon, France.

Society of Gynecologic Oncology Winter Meeting 2025. Jan 30 – Feb 1, 2025

Kim SR. Updates on fertility-sparing management of endometrial cancer. Society of Gynecologic Oncology Winter Meeting, Vancouver, Canada.

Veterinary Society of Surgical Oncology 2025 Conference. April 20-23, 2025

Ferguson SE. Near Infrared Fluorescence Using Indocyanine Green to Guide Surgery in Gynecologic Oncology. Veterinary Society of Surgical Oncology, international Annual Meeting, Banff, Canada.

2025 Canadian International Sarcoma Symposium. May 8-9, 2025

Kim SR. Local management of uterine leiomyosarcoma. Canadian International Sarcoma Symposium, Toronto, Ontario, Canada.



National

The 40th Annual Canadian Association of Psychosocial Oncology Conference. April 23-25, 2025

Oral Plenary Presentations

Lau S, Manoj M, **Ferguson SE**, Li M, Gesink D, Deljoomanesh S, **Laframboise S**, Glass K, Panjwani A, **Kim SR**. A multidisciplinary healthcare provider perspective: a qualitative study of the supportive care needs of young patients with endometrial cancer. The Canadian Association of Psychosocial Oncology 2025 Conference, Toronto, Canada.

George M, Lheureux S, Gibbings P, **Philp L**, Rodin G. Feasibility and Timing of Managing Cancer and Living Meaningfully (CALM) in Newly Diagnosed and Recurrent Ovarian Cancer. The Canadian Association of Psychosocial Oncology 40th Annual Conference. Toronto, ON, Canada.

The Society of Gynecologic Oncology of Canada 46th Annual General Meeting. June 19-21, 2025

Oral Plenary Presentations

Bernardini M. A video presentation of Hyperthermic Intraperitoneal Chemotherapy administered after minimally invasive cytoreduction for ovarian cancer. Society of Gynecologic Oncology of Canada. Vancouver, British Columbia.

Hsieh A, Volfson E, **Bernardini M**, **Bouchard-Fortier G**, **Philp L**, **Hogen L**. BRCA and Homologous Recombination (HR) Status as Predictors of Surgical Outcomes in Advanced High-Grade Serous Ovarian Cancer. The Society of Gynaecologic Oncology of Canada 46th Annual Meeting, Vancouver, British Columbia, Canada.

Hsieh A, **Bernardini M**, **Bouchard-Fortier G**, **Philp L**, **Hogen L**. Minimally invasive HIPEC. The Society of Gynaecologic Oncology of Canada 46th Annual Meeting, Vancouver, British Columbia, Canada.

Ahmed A, Saini G, Fazelzad R, Han K, Pugh T, Wong D, Hodgson A, **Ferguson SE**, **Kim SR**. Prognostic value of circulating tumor DNA in endometrial cancer: a systematic review and meta-analysis. The Society of Gynecologic Oncology of Canada 2025 46th Annual General Meeting, Vancouver, Canada.

Lim J, Drost L, Fazelzad R, Li Q, Huszti E, Han K, Hodgson A, Pugh T, **Ferguson SE**, **Kim SR**. Survival of MLH1 promoter hypermethylated endometrial cancer: a systematic review and meta-analyses The Society of Gynecology Oncology of Canada 46th Annual General Meeting, Vancouver, Canada.

Posters

Mitric C, Boulos M, Cornel K., Kupets R. Conservative management of early-stage cervical cancer: a single centre experience. Society of Gynecologic Oncology of Canada annual meeting, Vancouver, BC.

Hsieh A, **Bernardini M**, **Bouchard-Fortier G**. Feasibility and outcomes of the HUGO RAS system robotic technology in gynecologic oncology.



Invited Speaker Presentations

MyGOALS Multidisciplinary Gynecologic Oncology Annual Lecture Series. November 22, 2024

Ferguson SE. Cancer Drug Approval and Implementation in Ontario. My Goals Annual Gynecologic Cancer Update.

Kim SR. Moderator for Key Updates in Gynecological Cancer. Multidisciplinary Gynecologic Oncology Annual Lecture Series, Toronto, Ontario, Canada.

50th Annual D.A. Boyes Society Meeting and Obstetrics and Gynaecology Clinical Review. November 29, 2024

Kim SR. Same day discharge after minimally invasive gynecologic oncology surgery: lessons learned. 50th Annual D.A. Boyes Society Meeting & Obstetrics and Gynecology Clinical Review, Vancouver, British Columbia, Canada.

McMaster University Grand Rounds. January 29, 2025

Ferguson SE. Clinical Importance of Standardized Reporting for Ovarian/Adnexal Masses: An Ontario Health – Cancer Care Ontario Quality Initiative. McMaster University Grand Rounds.

Gynecologic Oncology of Canada 25th Continuing Professional Development Meeting. April 24-25, 2025

Kim SR. Real world challenges in making adjuvant treatment decisions for patients with early stage endometrial cancer: Discussion/review of 5 cases. Gynecologic Oncology of Canada 25th Annual Continuing Professional Development Meeting, Toronto, Ontario, Canada.



Local

2024 Centre for Quality Improvement and Patient Safety Symposium, University of Toronto. November 19, 2024

Posters

Dunphy C, Macedo A, **Philp L**, Thayaparan S, Ashfaq A, Li M, Devonish S, Lovas M, Papadakos J, Hannon B, Patel K, Croke J. Leveraging the electronic medical record to drive improvements in symptom screening. Center for Quality Improvement and Patient Safety Symposium, University of Toronto, Toronto, ON, Canada.

Department of Obstetrics and Gynaecology 41st Annual Research Day, University of Toronto. May 2, 2025

Oral Plenary Presentations

Volfson E, **Bernardini M**, **Bouchard-Fortier G**, **Philp L**, **Hogen L**. BRCA and Homologous Recombination (HR) Status as Predictors of Surgical Outcomes in Advanced High-Grade Serous Ovarian Cancer. Department of Obstetrics and Gynaecology 41th Annual Research Day, University of Toronto. Toronto, ON.

Ahmed A, Saini G, Fazelzad R, Han K, Pugh T, Wong D, Hodgson A, **Ferguson SE**, **Kim SR**. Prognostic value of circulating tumor DNA in endometrial cancer: a systematic review and meta-analysis. University of Toronto Obstetrics and Gynecology Research Day 2025.

Lim J, Drost L, Fazelzad R, Li Q, Huszti E, Han K, Hodgson A, Pugh TJ, **Ferguson SE**, **Kim SR**. Survival outcomes of MLH1 promoter hypermethylated endometrial cancer: a systematic review and meta-analysis. University of Toronto Obstetrics and Gynecology Research Day 2025.

Posters

Mitric C, Yang K, Bhat G, LHeureux S, **Laframboise S**, Li X, **Bouchard-Fortier G**. Gestational Trophoblastic Disease: Does Centralization of Care Impact Clinical Management. University of Toronto Obstetrics and Gynaecology Research Day, University of Toronto, Toronto, Ontario, Canada.

Mejia-Gomez J, Wilkins K, Singh C, Dickson B, Hobson S, Philippopoulos E, **Ferguson SE**, Wolfman W, Murji A. Malignant Uterine PEComas in Pregnancy a case series and systematic review. Department of Obstetrics and Gynaecology 41st Annual Research Day, University of Toronto. Toronto, ON.



Invited Speaker Presentations

City Wide Grand Rounds, Department of Obstetrics and Gynecology, University of Toronto. November 8, 2024

Philp L. Advances in Ovarian Cancer Diagnosis, City Wide Grand Rounds, Department of Obstetrics and Gynecology, University of Toronto, Toronto ON, CAN.

16th Annual Women's Health Symposium, Unity Health. January 10, 2025

Bouchard-Fortier G. O-RADS Unveiled – Navigating the New Frontier in Adnexal Mass Assessment. 16th Annual Women's Health Symposium. Unity Health. Totonro, Ontario, Canada.

Surgical Pathology Education Day, University of Toronto. February 1-2, 2025

Philp L. Surgical Management of Gynecologic Malignancies, Surgical Pathology Education Day, University of Toronto, Toronto ON, CAN.

Department of Mechanical and Industrial Engineering, University of Toronto. March 24, 2025


Philp L. Robotic Assisted Surgery, MIE1080: Introduction to Healthcare Robotics, Department of Mechanical and Industrial Engineering, University of Toronto, Toronto ON, CAN.

Clinician Investigator Program Seminar Series, University of Toronto. June 17, 2025

Philp L. Dason S. Family Planning in a Medical Career, Clinician Investigator Program Seminar Series, University of Toronto, Toronto ON, CAN.



PUBLICATIONS



First and Last Author

1. **Mitric C**, Sayyid RK, Fleshner NE, Hong NJ, **Bouchard-Fortier G**. Hysterectomy versus chemotherapy for low-risk non-metastatic gestational trophoblastic neoplasia (GTN): A cost-effectiveness analysis. *Gynecologic Oncology*. 2024 May 4;187:30-6. DOI: 10.1016/j.ygyno.2024.04.014.
2. **Hogen L**, Siriwardena T, Salman L, Bernardini MQ, Ferguson SE, Laframboise S, Bouchard-Fortier G, Atenafu EG, May T. Factors influencing surgeons' decision for diverting ileostomy and associated complications in ovarian cancer cytoreductive surgery. *International Journal of Gynecological Cancer*. 2025 Apr 1;35(4):101640. DOI: 10.1016/j.ijgc.2025.101640
3. **Bouchard-Fortier G**, Glanc P, Ferguson SE, Elman D, Kupets R, Po L, Taleghani S, Lo L, Hack K. Implementation of O-RADS Ultrasound Reporting System: A Quality Improvement Initiative. *Canadian Association of Radiologists Journal*. 2025:08465371241301335. DOI: 10.1177/08465371241301335
4. **Bouchard-Fortier G**, Gien LT, Chan WC, Lin Y, Krzyzanowska MK, **Ferguson SE**. The impact of perioperative transfusions on the oncologic outcomes of patients with ovarian cancer: A population-based study. *Journal of Surgical Oncology*. 2024 Aug 27;130(8):1717-24. DOI: 10.1002/jso.27840



5. Alkhanbouli M, Hana T, Laframboise S, **Bouchard-Fortier G**. Spontaneous Uterine Rupture of a High-Risk Gestational Trophoblastic Neoplasia. *Journal of obstetrics and gynaecology Canada: JOGC= Journal d'obstetrique et gynecologie du Canada: JOGC*. 2024 Jul;46(7):102563. DOI: 10.1016/j.jogc.2024.102563
6. Dzyubak O, Glass K, Watts M, Tarafdar O, Simpson AN, Maganti M, Deljoomanesh S, Laframboise S, Bernardini MQ, Pakbaz S, Hodgson A, Clarke B, Rouzbahman M, Chawla T, Zad T, **Kim SR, Ferguson SE**. Oncologic and fertility outcomes of progestin therapy for atypical hyperplasia and grade 1 cancer of the endometrium: Results of a specialized oncofertility program. *Gynecol Oncol*. 2025 Jun 30;199:72-78. DOI: 10.1016/j.ygyno.2025.06.015.
7. Moshkovich M, Volfson E, Cusimano RJ, Witheford M, Bernardini MQ, Koen J, **Kim SR**. Management of intravenous leiomyomatosis: a case report illustrating two distinct surgical approaches. *Gynecol Oncol Rep*. 2025 May 6;59:101762. DOI: 10.1016/j.gore.2025.101762.
8. Salman L, Cybulska P, Fowler R, Maganti M, Metser U, **Ferguson SE**. Simple perinephric adipose tissue measurement for prediction of failed sentinel lymph node mapping in endometrial cancer . *International Journal of Gynecological Cancer*. 2025 May 23:101949. DOI: 10.1016/j.ijgc.2025.101949
9. Classen CC, Chivers ML, Brotto LA, Barbera L, Carter J, Koval J, Robinson JW, **Ferguson SE**. A Randomized Controlled Trial of an Online Support Group Addressing Psychosexual Distress Among Women Treated for Gynecologic Cancer. *Gynecologic Oncology*. 2024 Nov 14;192:73-79. DOI: 10.1016/j.ygyno.2024.10.032
10. **Kim SR**, Oldfield L, Kim RH, Espin-Garcia O, Han K, Vicus D, Eiriksson L, Tone A, Pollett A, Cesari M, Clarke B, Bernardini M, Pugh TJ, **Ferguson SE**. Molecular classification of endometrial cancers using an integrative DNA sequencing panel. *Journal of Surgical Oncology*. 2024 Nov 5. DOI: 10.1002/jso.27973
11. **Ferguson S.E.**, Plante M., Kwon J.S., Samouelian V., Ferron G., Maulard A., Dekroon C., Van Driel W., Tidy J., Williamson K., Mahner S., Kommoss S., Goffin F., Tamussino K., Eyjolfssdottir B., Kim J., Gleeson N., Tu D., Shepherd L., Brotto L. Sexual health and quality of life in patients with low-risk early-stage cervical cancer: results from SHAPE/CX5 a randomized trial comparing simple versus radical hysterectomy. *Journal of Clinical Oncology*. 2024 Oct 1. DOI: 10.1200/JCO.24.00440
12. Saini A, Orav JE, Sisodia RC, **Philp L**. Cognitive deficit identified via pre-operative patient reported outcome measures is a predictor for post-operative health care utilization in gynecologic oncology patients. *Journal of Gynecologic Oncology*. 2025 Feb 20;36(4):e60. DOI: 10.3802/jgo.2025.36.e60



Co-Author

1. Lok C, Van Trommel N, Braicu EI, Planchamp F, Berkowitz R, Seckl M, EOTTD-ESGO-GCIG-ISSTD Guideline Committee. Practical Guidelines for the Treatment of Gestational Trophoblastic Disease: Collaboration of the European Organisation for the Treatment of Trophoblastic Disease (EOTTD)–European Society of Gynaecologic Oncology (ESGO)–Gynecologic Cancer InterGroup (GCIG)–International Society for the Study of Trophoblastic Diseases (ISSTD). *Journal of Clinical Oncology*. 2025 May 13;JCO-24. DOI: 10.1200/JCO-24-02326. Co-Author (**Bouchard-Fortier**)
2. Kozak M, Madariaga A, Gavrylyuk Y, **Bouchard-Fortier G**, Bowering V, Jivraj N, Truong T, Lovas M, Lane K, **Kim SR**, Badzynski A. Clinician perceptions of asynchronous care for patients with ovarian cancer on PARP inhibitor therapy. *International Journal of Gynecological Cancer*. 2025 May 1;35(5):101788. DOI: 10.1016/j.ijgc.2025.101788
3. Bhayana R, Jajodia A, Chawla T, Deng Y, **Bouchard-Fortier G**, Haider M, Krishna S. Accuracy of Large Language Model–based Automatic Calculation of Ovarian-Adnexal Reporting and Data System MRI Scores from Pelvic MRI Reports. *Radiology*. 2025 Apr 1;315(1):e241554. DOI: 10.1148/radiol.241554
4. Bekhor EY, Klein E, Shmilovich H, Marom G, Glazer Y, **Bouchard-Fortier G**, Harris M, Shlomovitz E. Self-expanding metallic stent insertion for malignant bowel obstruction secondary to gynecologic malignancies: a retrospective analysis: SEMS for gynecological MBO is efficient. *Surgical Endoscopy*. 2024 Feb;39(2):1147-52. DOI: 10.1007/s00464-024-11483-6
5. Nguyen JM, Zigras T, Gayowsky A, Marcucci M, Vicus D, Nica A, **Hogen L**, Costa A, Perez R. Association of frailty with perioperative and survival outcomes in patients with gynecologic cancers: A population-based study. *Gynecologic Oncology*. 2025 Jul 1;198:137-45. DOI: 10.1016/j.ygyno.2025.05.021.
6. Salman L, **Hogen L**, Maganti M, May T, Crean V. Anastomotic diversion rates following integration of indocyanine green fluorescence angiography in cytoreductive surgery for ovarian cancer. *International Journal of Gynecological Cancer*. 2024 Nov 1;34(11):1775-9. DOI: 10.1136/ijgc-2024-005753
7. Wenzel L, McKinney C, Jensen S, Peipert D, Ganatra S, Bredle J, Sisodia R, Doll KM, **Philp L**, Arend R, Dholakia J. Ensuring relevance and equity in patient reported outcomes (PROs) in endometrial cancer: The SGO promote study (Patient Reported Outcomes Measurement Opportunities Through Equity). *Gynecologic oncology*. 2025 Mar 1;194:137-44. DOI: 10.1016/j.ygyno.2025.02.020
8. Brown A, Gervais NJ, Gravelsins L, Zhao S, Duchesne A, Rieck J, Mouzenian A, Calvo N, Mazloum-Farzaghi N, Olsen R, Barensen M, Shao Z, **Bernardini M**, Jacobson M, Rajah MN, Grady C, Einstein G. Effects of Early Midlife Ovarian Removal on Medial Temporal Lobe Gray Matter Volume and Recognition Memory. *Hippocampus*. 2025 May;35(3):e70012. DOI: 10.1002/hipo.70012.
9. Chung DC, Shakfa N, Vakharia J, Warner K, Jacquelot N, Sayad A, Han S, Ghaedi M, Garcia-Batres CR, Sotty J, Azarmina A, Nowlan F, Chen ELY, Zon M, Elford AR, Wang BX, Nguyen LT, Mrkonjic M, Clarke BA, **Bernardini M**, Haibe-Kains B, **Ferguson SE**, Crome SQ, Jackson HW, Ohashi PS. CD103+CD56+ ILCs Are Associated with an Altered CD8+ T-cell Profile within the Tumor Microenvironment. *Cancer Immunol Res*. 2025 Apr 2;13(4):527-546. DOI: 10.1158/2326-6066.CIR-24-0151.
10. Brown A, Gravelsins L, Gervais NJ, Rieck J, Zhao S, Duchesne A, Witt ST, Kämpe R, Olsen R, Barensen M, Classon E, Theodorsson E, Ernerudh J, Åvall-Lundqvist E, Kjølhede P, Engström M, Shao Z, **Bernardini M**, Jacobson M, Rajah MN, Grady C, Einstein G. Early midlife ovarian removal



is associated with lower posterior hippocampal function. *Alzheimers Dement.* 2025 Feb;21(2):e14447. DOI: 10.1002/alz.14447.

11. Brown A, Gervais NJ, Gravelsins L, O'Byrne J, Calvo N, Ramana S, Shao Z, **Bernardini M**, Jacobson M, Rajah MN, Einstein G. Effects of early midlife ovarian removal on sleep: Polysomnography-measured cortical arousal, homeostatic drive, and spindle characteristics. *Horm Behav.* 2024 Sep;165:105619. DOI: 10.1016/j.yhbeh.2024.105619
12. Huband H, McGarragle KM, Hare CJ, Aronson M, Ward T, Semotiuk K, **Ferguson SE**, Cohen Z, Hart TL. Psychological impact of risk-reducing surgery for gynecologic cancer among women with Lynch syndrome. *Gynecologic Oncology Reports.* 2025 Apr 1;58:101719. DOI: 10.1016/j.gore.2025.101719
13. Huband H, McGarragle KM, Hare CJ, Aronson M, Ward T, Semotiuk K, **Ferguson SE**, Cohen Z, Hart TL. Gynecologic cancer screening among women with Lynch syndrome: Information and healthcare access needs. *Patient Education and Counseling.* 2025 Feb 1;131:108576. DOI: 10.1016/j.pec.2024.108576
14. Aronson M, Palma, L, Semotiuk K, Nuk J, Pollett A, Singh H, Rothenmund H, Racher H, Jessen J, Rusnak A, Rutka M, Etchegary H, Tiano T, Kaurah P, Dawson L, Hawrysh A, Ward T, Bedard A, Lerner-Ellis J, Jacob K, **Ferguson SE**, Kim C, Chamberlain E, Dornan K, Waldman L, Holter S, Horte J, Hyde A, Kwon J, MacMillan A, O'Loughlin M, Tabori U, Gallinger S, Ram R. Canadian Consensus for the Assessment and Follow-up for Lynch Syndrome. *Journal of Medical Genetics.* 2025 Mar 12. DOI: 10.1136/jmg-2024-110465
15. Plante M, Mahner S, Sebastianelli A, Bessette P, Lambaudie E, Guyon F, Piek J, Smolders R, Tidy J, Williamson K, Hanker L, Goffin F, Tsibula I, Eyjolfssdottir B, Gleeson N, Lee J, Ke Y, Kwon JS, **Ferguson SE**, Shepherd L, Tu D. Minimally invasive compared to open surgery in patients with low-risk cervical cancer following simple hysterectomy: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian Cancer Trials Group CX. 5/SHAPE trial. *International Journal of Gynecological Cancer.* 2025 Jan 1;35(1):100001. DOI: 10.1016/j.ijgc.2024.100001
16. Pritlove C, Capone G, Ramasamy M, Avery L, Fierini D, **Ferguson SE**, Han K, Jones JM. Eliminating Digestive Irregularities Caused by Late Effects: A Pilot Study of an Innovative Culinary Nutrition Intervention for Reducing Gastrointestinal Toxicity in Gynecologic Cancer Patients Who Have Undergone Pelvic Radiotherapy. *Nutrients.* 2024 Dec 6;16(23):4227. DOI: 10.3390/nu16234227.
17. Nica A, Sutradhar R, Kupets R, Covens A, Vicus D, Li Q, **Ferguson SE**, Gien LT. Effect of fragmentation of surgery and adjuvant treatment in high-grade nonendometrioid endometrial cancer: a population-based cohort study. *American Journal of Obstetrics and Gynecology.* 2024 Nov 15. DOI: 10.1016/j.ajog.2024.11.015
18. Kwon JS, Plante M, **Ferguson SE**, McTaggart-Cowan H, Samouëlian V, Ferron G, Maulard A, Lambaudie E, Tidy J, Williamson K, Gleeson N, Brotto L, Yeung S, Khabra N, Pataky R, Chan K, Cheung M, Ubi J, Tu D, Shepherd LE. Cost-effectiveness analysis of simple hysterectomy compared to radical hysterectomy for early cervical cancer from the CCTG CX.5 "SHAPE" Phase III clinical trial. *Journal of Gynecologic Oncology.* 2024 Oct 18;35(6):. DOI: 10.3802/jgo.2024.35.e117
19. Chuk E, Conway JL, Hanuschak J, Conroy L, Han K, Milosevic M, Lukovic J, **Ferguson SE**, Salman A, Santiago AT, Rink A, Croke J. Patient-reported sexual health outcomes of cervical cancer patients treated with definitive chemoradiation and MRI-guided brachytherapy. *Gynecologic Oncology.* 2024 Aug. DOI: 10.1016/j.ygyno.2024.08.022.
20. Swift B, Axelrod C, Benseler A, Kobylanskii A, Vicus D, **Laframboise S**, Walker M, Sobel M, Tannenbaum E. A Multi-centre, Randomized Controlled Trial to Assess Video-based Surgical Coaching in Gynecology. *J Minim Invasive Gynecol.* 2025 Mar 24:S1553-4650(25)00086-X. DOI:10.1016/j.jmig.2025.03.001.



21. Touhami O, De Guerke L, Fortin L, Foo J, Provencher D, Samouelian V, Cormier B, Lau S, Salvador S, Gotlieb W, Gilbert L, **Laframboise S**, Altman A, Ghatage P, Brar H, Kwon K, Le T, Sebastianelli A, Fokom Domgue J, Plante M. Global Distribution and Career Outcomes of International Fellows Trained in Canadian Gynecologic Oncology Programs. *Gynecol Oncol Rep*. 2024 Sep 16;56:101512. DOI: 10.1016/j.gore.2024.101512
22. Renton M, Fakhriyehasl M, WeissJ, Milosevic M, **Laframboise S**, Rouzbahman M, Han K, Jhaveri K. Multiparametric MRI Radiomics for Predicting Disease-Free Survival and High-Risk Histopathological Features for Tumor Recurrence in Endometrial Cancer. *Frontiers in Oncology*. 2024 Aug 2;14:1406858. DOI: 10.3389/fonc.2024.1406858
23. Kozak M, Madariaga A, Gavrylyuk Y, **Bouchard-Fortier G**, Bowering V, Jivraj N, Truong T, Lovas M, Lane K, Kim SR, Badzynski A. Clinician perceptions of asynchronous care for patients with ovarian cancer on PARP inhibitor therapy. *International Journal of Gynecological Cancer*. 2025 May 1;35(5):101788. DOI: 10.1016/j.ijgc.2025.101788
24. Hogen L, Siriwardena T, Salman L, **Bernardini MQ**, **Ferguson SE**, **Laframboise S**, **Bouchard-Fortier G**, Atenafu EG, May T. Factors influencing surgeons' decision for diverting ileostomy and associated complications in ovarian cancer cytoreductive surgery. *International Journal of Gynecological Cancer*. 2025 Apr 1;35(4):101640. DOI: 10.1016/j.ijgc.2025.101640
25. Bouchard-Fortier G, Glanc P, **Ferguson SE**, Elman D, Kupets R, Po L, Taleghani S, Lo L, Hack K. Implementation of O-RADS Ultrasound Reporting System: A Quality Improvement Initiative. *Canadian Association of Radiologists Journal*. 2025 Jan 8;08465371241301335. DOI: 10.1177/08465371241301335
26. Alkhanbouli M, Hana T, **Laframboise S**, Bouchard-Fortier G. Spontaneous Uterine Rupture of a High-Risk Gestational Trophoblastic Neoplasia. *Journal of obstetrics and gynaecology Canada*. 2024 Jul;46(7):102563. DOI: 10.1016/j.jogc.2024.102563
27. Dzyubak O, Glass K, Watts M, Tarafdar O, Simpson AN, Maganti M, Deljoomanesh S, **Laframboise S**, **Bernardini M**, Pakbaz S, Hodgson A, Clarke B, Rouzbahman M, Chawla T, Zad T, Kim SR, Ferguson SE. Oncologic and fertility outcomes of progestin therapy for atypical hyperplasia and grade 1 cancer of the endometrium: Results of a specialized oncofertility program. *Gynecol Oncol*. 2025 Jun 30;199:72-78. DOI: 10.1016/j.ygyno.2025.06.015.
28. Moshkovich M, Volfson E, Cusimano RJ, Witheford M, **Bernardini M**, Koen J, Kim SR. Management of intravenous leiomyomatosis: a case report illustrating two distinct surgical approaches. *Gynecol Oncol Rep*. 2025 May 6;59:101762. DOI: 10.1016/j.gore.2025.101762.
29. Kim SR, Oldfield L, Kim RH, Espin-Garcia O, Han K, Vicus D, Eiriksson L, Tone A, Pollett A, Cesari M, Clarke B, **Bernardini M**, Pugh TJ, Ferguson SE. Molecular classification of endometrial cancers using an integrative DNA sequencing panel. *Journal of Surgical Oncology*. 2024 Nov 5. DOI: 10.1002/jso.27973
30. Chung DC, Shakfa N, Vakharia J, Warner K, Jacquelot N, Sayad A, Han S, Ghaedi M, Garcia-Batres CR, Sotty J, Azarmina A, Nowlan F, Chen ELY, Zon M, Flord AR, Wang BX, Nguyen LT, Mrkonjic M, Clarke BA, **Bernardini M**, Haibe-Kains B, **Ferguson SE**, Crome SQ, Jackson HW, Ohashi PS. CD103+ CD56+ ILCs Are Associated with an Altered CD8+ T-cell Profile within the Tumor Microenvironment. *Cancer Immunology Research*. 2025 Feb 14 ;13(4):527-46. DOI: 10.1158/2326-6066.CIR-24-0151
31. Bernard L, Pond GR, Elit L, Vicus D, Piedimonte S, Nelson G, Aubrey C, Plante M, Teo-Fortin LA, Lau S, Kwon J, **Kim SR**, Altman AD, Mercier NB, Willows K, Sadeq N, Feigenberg T, Sabourin J, Samouelian V, Helpman L. Safety of vaginal surgery for early-stage cervical cancer: A retrospective multicenter cohort study. *European Journal of Surgical Oncology*. 2024 Oct 1;50(10):108518. DOI: 10.1016/j.ejso.2024.108518



**Never Been
Done
Is
What We Do.**

